二氟泼尼酯滴眼液

Search documents
津药药业股份有限公司关于公司收到化学原料药上市申请批准通知书的公告
Shang Hai Zheng Quan Bao· 2025-08-29 21:40
Group 1 - The company has received the approval notice for the listing application of the chemical raw material drug Difluprednate from the National Medical Products Administration (NMPA) [1][3] - Difluprednate is a topical corticosteroid used to suppress inflammation caused by various irritants, primarily available in the form of eye drops for treating inflammation and pain related to eye surgeries [2][3] - The global sales figures for Difluprednate formulations are projected to be $49 million in 2023 and $41 million in 2024, indicating a potential market opportunity for the company [3] Group 2 - The approval of the raw material drug will enhance the company's product portfolio and leverage its integrated advantages in raw material and formulation production, aiding in business expansion [4] - The company has invested approximately 2.6 million yuan in the research and development of the Difluprednate raw material project [3]
中国医药上半年净利润2.94亿元;治疗不孕不育长效注射液获批
2 1 Shi Ji Jing Ji Bao Dao· 2025-08-28 00:05
Policy Developments - The State Council aims to develop the China (Jiangsu) Pilot Free Trade Zone into a globally influential biopharmaceutical industry hub, with a plan that includes 18 key tasks for integrated innovation across the entire industry chain by 2030 [1] Drug Approvals - China Resources Double Crane announced that its subsidiaries received drug registration certificates for three products, which will enhance the company's product line and market competitiveness [2] - Tianyao Pharmaceutical's subsidiary received a drug registration certificate for a new eye drop product, which is expected to positively impact the company's domestic market expansion and performance [3] Financial Reports - China National Pharmaceutical Group reported a revenue of 17.076 billion yuan for the first half of 2025, a decrease of 6.71% year-on-year, with a net profit of 294 million yuan, down 16.19% [4] - Jiahe Meikang reported a revenue of 219 million yuan for the first half of 2025, a decline of 27.22%, resulting in a net loss of 116 million yuan [5] - Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a decrease of 6.20%, but a net profit increase of 3.92% to 1.155 billion yuan [6] Investment Activities - Tibet Pharmaceutical plans to invest 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake, focusing on gene editing technologies [7] Industry Developments - The first long-acting injection for infertility treatment has been approved, providing a more efficient and convenient option for patients compared to traditional daily injections [8] - A study revealed a protein linked to infertility and cancer, suggesting potential new treatment avenues for both conditions [9] Shareholder Actions - Dabo Medical announced a plan for a shareholder to reduce their stake by up to 2% of the company's shares [10] - Kangchen Pharmaceutical's executive plans to sell up to 87,500 shares due to personal financial needs [11]
津药药业股价下跌4.22% 子公司获批国内首仿滴眼液
Jin Rong Jie· 2025-08-27 19:22
Group 1 - The stock price of Tianyao Pharmaceutical closed at 4.31 yuan on August 27, down 0.19 yuan or 4.22% from the previous trading day [1] - The company operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of steroid hormone and amino acid raw materials and formulations [1] - Tianyao Pharmaceutical is recognized as a national high-tech enterprise and is a global leader in amino acid raw material manufacturing [1] Group 2 - On the evening of August 27, Tianyao Pharmaceutical announced that its subsidiary Tianyao Heping received approval from the National Medical Products Administration for the registration certificate of Difluprednate Eye Drops, which is the first generic version in China [1] - The drug is primarily used for treating inflammation and pain related to eye surgeries, with a cumulative R&D investment of approximately 53.27 million yuan [1] - According to IQVIA data, the global sales for this drug are projected to be 33 million USD in 2023 and 24 million USD in 2024 [1] Group 3 - On August 27, the net inflow of main funds into Tianyao Pharmaceutical was 7.69 million yuan, accounting for 0.16% of the circulating market value [1] - Over the past five days, the net inflow of main funds totaled 34.99 million yuan, representing 0.74% of the circulating market value [1]
津药药业:子公司获得药品注册证书
Zheng Quan Ri Bao Wang· 2025-08-27 12:42
Group 1 - The core point of the article is that Tianjin Pharmaceutical Co., Ltd. (津药药业) announced the approval of its subsidiary Tianjin Peace Pharmaceutical Co., Ltd. for the drug registration certificate of Difluprednate Eye Drops by the National Medical Products Administration [1] Group 2 - The approval signifies a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1] - Difluprednate is a corticosteroid used for the treatment of inflammation and pain associated with eye surgery, indicating potential market demand [1] - The registration certificate allows the company to market and sell the product, which could enhance its revenue streams [1]
津药药业:“二氟泼尼酯滴眼液”取得注册证
Mei Ri Jing Ji Xin Wen· 2025-08-27 09:01
Group 1 - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd., received the drug registration certificate for Difluprednate Eye Drops from the National Medical Products Administration [1] - The product is officially named "Difluprednate Eye Drops" [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related listed companies [1]
津药药业:子公司津药和平获二氟泼尼酯滴眼液药品注册证书
Xin Lang Cai Jing· 2025-08-27 07:44
Core Viewpoint - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received the drug registration certificate for Difluprednate Eye Drops from the National Medical Products Administration, marking it as the first generic version in China [1] Group 1: Product Development - The drug is primarily used for treating inflammation and pain related to eye surgeries [1] - The total research and development investment for this project has reached approximately 53.27 million yuan [1] Group 2: Market Potential - The projected global sales for Difluprednate Eye Drops are estimated to be 33 million USD in 2023 and 24 million USD in 2024 [1]